Sample size -n (%) |
14624 |
10634 (72.7) |
2571 (17.6) |
1419 (9.7) |
15496 |
12400 (80.0) |
2233 (14.4) |
863 (5.6) |
Sociodemographics |
Age—mean (SD) |
57.5 (4.4) |
57.1 (4.3) |
58.2 (4.3) |
59.1 (4.2) |
57.5 (4.3) |
57.3 (4.3) |
58.2 (4.3) |
58.8 (4.0) |
Education, highest level |
< Compulsory school (%) |
100 (0.7) |
59 (0.6) |
23 (0.9) |
19 (1.4) |
95 (0.6) |
58 (0.5) |
26 (1.2) |
11 (1.3) |
Compulsory school (%) |
1382 (9.9) |
1734 (7.7) |
497 (10.7) |
318 (14.7) |
1137 (7.6) |
822 (6.8) |
217 (10.0) |
111 (13.4) |
Upper Secondary Highschool (%) |
6798 (48.6) |
9971 (44.4) |
2268 (48.8) |
1083 (50.0) |
6350 (42.5) |
5075 (41.9) |
954 (44.0) |
404 (48.9) |
University (%) |
5712 (40.8) |
10638 (47.7) |
1834 (39.5) |
733 (33.9) |
7344 (49.2) |
6170 (50.9) |
973 (44.8) |
300 (36.3) |
History of cardiovascular disease |
Previous MI, CABG or PCI n (%) |
541 (3.7) |
254 (2.4) |
154 (6.0) |
129 (9.1) |
152 (1.0) |
74 (0.6) |
37 (1.7) |
41 (1.7) |
Family history of cardiovascular diseases |
MI, subjects’ parent or sibling n (%) |
3589 (26.2) |
2561 (25.6) |
629 (26.2) |
399 (31.7) |
4606 (31.5) |
3618 (30.7) |
702 (33.8) |
286 (37.0) |
Stroke subjects’ parent or sibling n (%) |
3462 (25.5) |
2467 (24.9) |
654 (27.4) |
332 (26.8) |
4300 (29.6) |
3428 (29.4) |
612 (29.8) |
260 (33.2) |
Medication |
Antihypertensive agents n (%) |
3030 (21.6) |
1687 (16.5) |
681 (27.7) |
662 (49.6) |
2733 (18.2) |
1829 (15.2) |
546 (25.4) |
358 (43.6) |
Lipid lowering agents n (%) |
1386 (9.9) |
640 (6.3) |
317 (12.9) |
429 (32.2) |
911 (6.1) |
480 (4.0) |
182 (8.5) |
249 (30.3) |
Glucose lowering agents (oral only) n (%) |
– |
– |
– |
696 (52.3) |
– |
– |
– |
378 (46.4) |
Insulin only or insulin + oral treatment |
|
|
|
242 (30.4) |
|
|
|
121 (25.8) |
Anthropometry |
BMI, kg/m2 median (Q1–Q3) |
26.9 (24.8–29.6) |
26.4 (24.4–28.9) |
27.9 (25.6–30.6) |
29.3 (26.8–32.7) |
25.7 (23.1–29.1) |
25.1 (22.8–28.2) |
27.7 (24.6–31.6) |
30.0 (26.4–34.1) |
Waist Circumference, cm median (Q1–Q3) |
99.0 (92.0–106.0) |
97.0 (91.0–104.0) |
102.0 (96.0–110.0) |
106.0 (99.0–115.0) |
88.0 (80.0–97.0) |
86.0 (79.0–95.0) |
94.0 (85.0–103.0) |
100.0 (91.0–110.0) |
Life style |
Current smoking status |
Current |
1191 (11.6) |
1191 (11.6) |
385 (15.6) |
220 (16.5) |
1432 (11.9) |
1432 (11.9) |
353 (16.4) |
145 (17.7) |
Ex-smoker (regardless of cessation time) |
3302 (32.2) |
3302 (32.2) |
910 (37.0) |
540 (40.4) |
4623 (38.5) |
4623 (38.5) |
875 (40.7) |
338 (41.2) |
Never |
5764 (56.2) |
5764 (56.2) |
1167 (47.4) |
575 (43.1) |
5956 (49.6) |
5956 (49.6) |
921 (42.9) |
337 (41.1) |
Pack-years—median (Q1–Q3) |
13.0 (5.5–25.0) |
12.0 (5.0–23.3) |
15.0 (6.8–27.8) |
18.0 (9.3–30.6) |
12.0 (5.0–21.5) |
11.1 (4.5–20.5) |
13.8 (6.0–24.8) |
18.5 (9.9–29.3) |
Physical activity (min/day) |
Sedentary median (Q1–Q3) |
180 (120–255) |
182 (121–253) |
187 (127–263) |
203 (137–287) |
151 (102–217) |
151 (103–215) |
154 (103–225) |
174 (113–249) |
Low-intensity median (Q1–Q3) |
330 (272–393) |
328 (273–389) |
329 (272–394) |
309 (254–373) |
363 (307–422) |
362 (308–423) |
370 (309–431) |
348 (286–414) |
Moderate- and vigorous median (Q1–Q3) |
49.0 (32.0–71.0) |
54.0 (37.0–75.0) |
52.0 (35.0–73.0) |
43.0 (28.0–65.0) |
48.0 (32.0–67.0) |
51.0 (36.0–70.0) |
47.0 (32.0–67.0) |
41.0 (26.0–59.0) |
Laboratory measurements |
Fasting glucose, mmol/l—mean (SD) |
5.7 (1.3) |
5.3 (0.5) |
6.3 (0.4) |
8.3 (2.5) |
5.5 (1.0) |
5.2 (0.5) |
6.2 (0.5) |
7.9 (2.4) |
HbA1c, mmol/mol—mean (SD) |
36.9 (7.2) |
34.8 (3.1) |
37.7 (4.0) |
51.0 (14.5) |
36.3 (5.7) |
35.0 (3.0) |
38.3 (4.1) |
49.3 (14.1) |
HbA1c, % |
5.5 |
5.4 |
5.6 |
6.8 |
5.4 |
5.4 |
5.6 |
6.6 |
High sensitivity CRP, mg/L—mean (SD) |
2.1 (4.6) |
1.9 (3.8) |
2.4 (4.5) |
3.1 (8.6) |
2.2 (4.1) |
1.9 (3.7) |
3.0 (5.3) |
3.5 (4.8) |
Total cholesterol, mmol/L—mean (SD) |
5.32 (1.06) |
5.45 (1.00) |
5.13 (1.06) |
4.65 (1.11) |
5.64 (1.02) |
5.70 (1.00) |
5.52 (1.01) |
5.08 (1.15) |
HDL, mmol/L—mean (SD) |
1.41 (0.40) |
1.45 (0.39) |
1.37 (0.38) |
1.24 (0.37) |
1.83 (0.50) |
1.88 (0.49) |
1.71 (0.45) |
1.54 (0.50) |
LDL, mmol/L—mean (SD) |
3.43 (0.97) |
3.56 (0.93) |
3.27 (0.96) |
2.84 (1.01) |
3.45 (0.96) |
3.49 (0.95) |
3.39 (0.94) |
3.02 (1.07) |
Remnant, mmol/L—mean (SD) |
0.47 (0.41) |
0.46 (0.40) |
0.49 (0.44) |
0.57 (0.41) |
0.36 (0.34) |
0.33 (0.33) |
0.43 (0.33) |
0.50 (0.38 |
Triglycerides, mmol/L—mean (SD) |
1.4 (1.0) |
1.3 (0.9) |
1.4 (1.2) |
1.8 (1.4) |
1.1 (0.6) |
1.1 (0.5) |
1.2 (0.7) |
1.6 (1.1) |
eGFR ml/min/1,73 m2 mean (SD) |
85.3 (11.8) |
84.7 (11.5) |
85.9 (12.2) |
88.3 (13.1) |
84.4 (12.4) |
84.1 (12.2) |
85.2 (12.4) |
87.1 (13.9) |
eGFR, ml/min/1,73 m2 < 60 n (%) |
299 (2.0) |
190 (1.8) |
58 (2.3) |
51 (3.6) |
409 (2.6) |
325 (2.6) |
54 (2.4) |
30 (3.5) |
Clinical characteristics |
Diabetes duration, years- mean (SD) |
– |
– |
– |
9.3 (9.1) |
– |
– |
– |
10.9 (11.7) |
Systolic blood pressure, mmHg—mean (SD) |
128.8 (15.6) |
127.5 (15.4) |
131.4 (15.5) |
133.8 (16.1) |
123.2 (17.8) |
122.2 (17.7) |
126.5 (17.7) |
129.0 (16.8) |
Diastolic blood pressure, mmHg—mean (SD) |
78.5 (10.1) |
78.0 (10.2) |
79.8 (9.9) |
80.2 (9.9) |
76.6 (10.8) |
76.2 (10.8) |
78.3 (10.7) |
78.8 (9.9) |
Ankle-brachial index—median (IQR) |
1.23 (1.17, 1.29) |
1.23 (1.17, 1.29) |
1.22 (1.16, 1.28) |
1.21 (1.15, 1.27) |
1.19 (1.10, 1.24) |
1.19 (1.13, 1.26) |
1.18 (1.11, 1.24) |
1.17 (1.10, 1.24) |
Ankle-brachial index < 0.9 n (%) |
49 (0.4) |
31 (0.2) |
19 (0.4) |
27 (1.4) |
28 (0.2) |
12 (0.1) |
9 (0.5) |
7 (0.9) |
CACS ≥ 100 |
2657 (19.1) |
1647 (16.1) |
552 (21.1) |
458 (35.3) |
908 (6.1) |
590 (4.9) |
190 (8.9) |
128 (15.9) |
Any carotid plaque (≥ 1 vessel) |
8928 (61.6) |
6342 (60.0) |
1590 (62.6) |
996 (71.2) |
7536 (49.1) |
5888 (47.9) |
1153 (52.2) |
495 (58.6) |